The Neuromuscular Junction—Basic Receptor Pharmacology

  • J. A. Jeevendra Martyn


Shortly after the introduction of neuromuscular (NM) relaxants to clinical practice, it became apparent that certain pathological states were associated with both hyper- and hyposensitivity to the NM effects of depolarizing or agonist-type, and antagonist or nondepolarizing muscle relaxants (NDMR).1 (Depolarizing relaxants such as succinyicholine, SCh and decamethonium should be considered AChR agonists since their pharmacological actions are like acetylcholine (ACh) in that, at least initially, they stimulate AChRs. NDMRs such as dTC are competitive antagonists of the AChRs because they competitively inhibit the effects of ACh). Reports of cardiac arrest, following succinyicholine were also reported to occur in certain patients.2 The availability of quantitative assays for drug concentrations and receptors, together with electrophysiologic and immunologic techniques, have enabled investigators to correlate these alterations in sensitivity of muscle relaxants to pharmacokinetic and pharmacodynamic changes. My lecture will specifically focus on the qualitative and quantitative changes in the nicotinic acetylcholine receptors (AChRs) at the muscle membrane and its relationship to NM relaxant sensitivity. Pathological states, including iatrogenic factors, and the molecular mechanisms, which may play a role in these AChR changes, will be also discussed.


Acetylcholine Receptor Neuromuscular Junction Muscle Membrane Competitive Antagonist Nondepolarizing Muscle Relaxant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dundee JW, Gray TC: Variations in response to relaxant drugs. Lancet 2:1015–1018, 1951PubMedCrossRefGoogle Scholar
  2. 2.
    Martyn JAJ, White DA, Gronert, Jaffe RS, Ward JM: Up-and-down regulation of skeletal muscle acetylcholine receptors. Anesthesiology 76:822–843, 1992PubMedCrossRefGoogle Scholar
  3. 3.
    Wonnacott S: The paradox of nicotinic acetylcholine receptor up-regulation by nicotine. Trends Pharmacol Sci 11:216–219, 1990PubMedCrossRefGoogle Scholar
  4. 4.
    Schuetze SM, Role LW: Developmental regulation of nicotinic acetylcholine receptors. Annu Rev Neurosci 10:403–457, 1987PubMedCrossRefGoogle Scholar
  5. 5.
    Gronert GA, Theye RA: Pathophysiology of hyperkalemia induced by succinylcholine. Anesthesiology 43:89–99, 1975PubMedCrossRefGoogle Scholar
  6. 6.
    Goldhill DR, Martyn JAJ: Succinylcholine induced hyperkalemia. Muscle Relaxants Ed Azar I. New York, Marcel Dekker, 1987, pp 93–113Google Scholar
  7. 7.
    Shayevitz JR, Matteo RS: Decreased sensitivity to metocurine in patients with upper motoneuron disease. Anesth Analg 65:767–772, 1985Google Scholar
  8. 8.
    Hogue CW, Itani MS, Martyn JAJ: Resistance to dTubocurarine in lower motor neuron injury is related to increased acetylcholine receptors at the neuromuscular junction. Anesthesiology 73:703–709, 1990PubMedCrossRefGoogle Scholar
  9. 9.
    Ward JM, Martyn JAJ: Bum injury-induced nicotinic acetylcholine receptor changes on muscle membrane. Muscle & Nerve 16:348–354, 1993CrossRefGoogle Scholar
  10. 10.
    Kim C, Martyn JA, Fuke N: Bum injury to trunk of rat causes denervation-like responses in gastrocnemius muscle. J Appl Physiol 65:1745–1751, 1988PubMedGoogle Scholar
  11. 11.
    Marathe PH, Haschke RH, Slattery JT, Zucker JR, Pavlin EG: Acetylcholine receptor density and acetylcholinesterase activity in skeletal muscle of rats following thermal injury. Anesthesiology 70:654–659, 1989PubMedCrossRefGoogle Scholar
  12. 12.
    Gronert GA, White DA, Shafer SL, Matteo RS: Exercise produces sensitivity to metocurine. Anesthesiology 70:973–977, 1989PubMedCrossRefGoogle Scholar
  13. 13.
    Yanez P, Itani MS, Martyn JAJ. D-tubocurarine infusion with and without immobilization causes hyperkalemia to succinylcholine. J Clin Pharmacol (Supplement) 1993; 33:1007Google Scholar
  14. 14.
    Tomera JF, Martyn JAJ: Intraperitoneal endotoxin but not protein malnutrition shifts dtubocurarine dose-respone curves in mouse gastrocnemius muscle. J Pharmacol Exp Ther 250:216–220, 1989PubMedGoogle Scholar
  15. 15.
    Sarubin J, Gebert E: Serum kaliumansteig nach depolarisierenden muskelrelaxantien. Anaesthetist 30:246–250, 1981Google Scholar
  16. 16.
    Berg DK, Hall ZW: Increased extrajunctional acetylcholine sensitivity produced by chronic post-synaptic neuromuscular blockade. J Physiol (Lond) 244:569–676, 1975Google Scholar
  17. 17.
    Hogue CW, Ward JM, Itani MS, Martyn JAJ: Tolerance and upregulation of acetylcholine receptors follows chronic infusion of d-tubocurarine. J Appl Physiol 72:1326–1331, 1992PubMedGoogle Scholar
  18. 18.
    Martyn JAJ, Kim C. D-tubocurarine accentuates the burn-induced upregulation of acetylcholine receptors at the muscle membrane. Crit. Care Med 1994, 22:A230CrossRefGoogle Scholar
  19. 19.
    Engel AG, Hutchinson DO, Nakano S, Murphy L, Griggs RC, Gu Y, Hall ZW, Lindstrom J: Myasthenia syndromes attributed to mutations affecting epsilon subunit of the acetylcholine receptor Ann NY Acad Sci 681:496–508, 1993Google Scholar
  20. 20.
    Ward JM, Rosen KM, Martyn JAJ. Acetylcholine receptor subunit mRNA changes in bums are different to that seen after denervation. J Bum Care Rehab 14:595–60, 1993CrossRefGoogle Scholar
  21. 21.
    Chance WT, Allmen D, Benson D, Zhang FS, Fischer JE: Clenbuterol decreases catabolism and increases hypermetabolism in burned rats. J Trauma 31:365–370, 1990CrossRefGoogle Scholar
  22. 22.
    Ross AF, Green WN, Hartmann DS Claudio: Efficiency of acetylcholine receptor subunit assembly and its regulation by CAMP. J Cell Biol 113:623–636, 1991PubMedCrossRefGoogle Scholar
  23. 22.
    Drachman DB: Myasthenia gravis. N Engl J Med 330:1797–1810, 1994PubMedCrossRefGoogle Scholar
  24. 23.
    Fambrough DM, Drachman DB, Satyamurti S: Neuromuscular junction in myasthenia gravis: Decreased acetylcholine receptors. Science 182:293–295, 1973PubMedCrossRefGoogle Scholar
  25. 24.
    Gwilt M, Wray D: The effect of chronic neostigmine treatment on channel properties at the rat neuromuscular junction. Br J Pharmacol 88:25–31, 1986PubMedCrossRefGoogle Scholar
  26. 25.
    Keeler JR, Hurst CG, Dunn MA: Pyridostigmine used as a nerve agent pretreatment under wartime conditins. JAMA 266:693–695, 1991PubMedCrossRefGoogle Scholar
  27. 26.
    Selden BS, Curry SC: Prolonged succinylcholine-induced paralysis in organophosphate insecticide poisoning. Ann Emerg Med 316:807–808, 1987Google Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • J. A. Jeevendra Martyn
    • 1
  1. 1.Harvard Medical School; Clinical and Biochemical Pharmacology Laboratory, Department of AnesthesiaMassachusetts General Hospital and Shriners Burns InstituteBostonUSA

Personalised recommendations